The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
The coordinators hired by Chicago Bears coach Ben Johnson enter their new jobs with vastly different amounts of coaching ...
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...
22hon MSN
Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...
We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback